Tenax Therapeutics LEVEL Trial Presentation
Analysis based on 6 articles · First reported Jul 02, 2026 · Last updated Jul 02, 2026
The announcement by Tenax Therapeutics regarding the upcoming presentation of its Phase 3 LEVEL clinical trial results at a major cardiology congress, coupled with the expectation of topline data in August, is a positive development for the company. This could lead to increased investor interest and a potential rise in the stock price of Tenax Therapeutics, especially if the results are favorable, as it addresses a significant unmet medical need.
Tenax Therapeutics, a Phase 3 development-stage pharmaceutical company, announced that the results from its Phase 3 LEVEL clinical trial will be presented in a Late-Breaking Clinical Science session at the European Society of Endocrinology (ESC) Congress 2026, held from August 28-31 in Munich, Germany. The company anticipates reporting topline data from the LEVEL trial in August 2026. Professor Sanjiv Shah, MD, from Northwestern University, will present the findings. The LEVEL trial evaluates TNX-103 (oral levosimendan) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) in the United States and Canada, with over 230 patients enrolled. A prespecified Blinded Sample Size Re-estimation in December 2025 indicated the trial is well-powered to detect a 25-meter change in the 6-minute walk distance, its primary endpoint.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard